$ALHC

KAO JOHN E sold $6.1M of ALHC (indirect holdings)

KAO JOHN E (Chief Executive Officer) sold 298,000 indirectly-held shares of Alignment Healthcare, Inc. (ALHC) at an average of $20.36 ($19.65–$20.60, $6.07M total) across 2 trades on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KAO JOHN E
Published Jun 12, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The CEO’s open-market sale totaling ~$6.07M is newly reported; the 10b5-1 designation reduces interpretive value regarding near-term fundamentals.

02

Market read

Provides a fresh, company-specific insider selling datapoint that can influence short-term sentiment but lacks fundamental catalysts.

03

What to watch

Traders may over-weight insider sales; without accompanying guidance/clinical/regulatory updates, the signal is typically weak.

Relevance 5/10Novelty 8/10Timing: SEC Form 4 filed June 12 (covering June 10 sales)

Background

The article is an SEC Form 4 insider transaction disclosure for Alignment Healthcare, Inc. (ALHC).

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

CEO KAO JOHN E sold $6.07M of Alignment Healthcare shares via an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be small unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is new and company-specific, but the transaction is explicitly under a pre-arranged 10b5-1 plan and provides no new operating/financial information.

Market effects

No direct sector read-through; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Alignment Healthcare, Inc.

    Company whose CEO insider sale is disclosed on SEC Form 4.

  • KAO JOHN E

    Chief Executive Officer and director who sold shares.

  • 10b5-1 plan

    Pre-arranged plan noted as Yes, indicating scheduled selling.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMed

Alignment Healthcare extends retreat, falls an additional 16% (ALHC:NASDAQ)

Alignment Healthcare (ALHC) shares fell 16% on Wednesday, extending a 20% drop from the prior session. Management cited planned investments and medical-cost pressures at the Baird 2026 Global Healthcare Conference. The stock reached a 52-week low at $8.71, trading 45-54% below its 50/200-day averages. An analyst upgraded ALHC to Buy, noting operational progress but warning of potential volatility.

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

$ALHCMed

ALHC Stock Tumbles After ‘Don’t Poke the Bear’ Silence On Star Ratings — CLOV Falls With It

Alignment Healthcare (ALHC) shares dropped 22% after executives declined to discuss next year's quality bonus and noted higher-than-expected hospital bills. CEO John Kao cited CMS sensitivity about commenting on Plan Preview 2. Clover Health (CLOV) also fell 9%. ALHC's CFO mentioned institutional cost headwinds but expects them to ease by 2027. Guidance remained unchanged.

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

$ALHCMed

Alignment Health seeks to have former exec's whistleblower suit tossed

Alignment Healthcare and executives filed to dismiss a whistleblower suit by former exec Hakan Kardes, who alleges earnings were artificially boosted for higher bonuses. The company claims Kardes resigned voluntarily and his claims are false. Kardes says he was forced out after reporting accounting irregularities, affecting EBITDA and executive bonuses. Shares dropped initially but rebounded.

$ALHCMed

Alignment Healthcare (ALHC) Stock Drops 16.7% After Whistleblower Accounting Allegations Trigger Securities Investigation

Kaplan Fox & Kilsheimer LLP said it is investigating potential securities violations at Alignment Healthcare, Inc. (NASDAQ: ALHC) after a whistleblower complaint alleging accounting irregularities that allegedly inflated previously reported and projected results. The complaint cites operating expenses allegedly misclassified as capital expenditures, affecting Adjusted EBITDA. On July 8, 2026, ALHC shares fell $4.02, or 16.7%, to close at $20.03.